Form 4: ResMed Director Peter C. Farrell Sells 2,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of common stock at a price of $219.74 per share under a pre-arranged 10b5-1 trading plan.
Summary
- On April 2, 2025, Peter C. Farrell, a director of ResMed Inc., sold 2,000 shares of ResMed common stock.
- The sale was executed at a price of $219.74 per share.
- Following the transaction, Farrell directly owns 73,218 shares of ResMed common stock.
- The sale was conducted under a Rule 10b5-1 plan adopted on May 28, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by company directors are a normal part of corporate governance. The fact that this sale was conducted under a 10b5-1 plan suggests it was pre-planned and not based on any inside information.
Stakeholder Impact
- The sale of shares by a director could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| May 28, 2024 | Date the Rule 10b5-1 plan was adopted |
| April 02, 2025 | Date of the transaction (stock sale) |
| April 03, 2025 | Date of signature |
Keywords
ResMed, Peter C. Farrell, Form 4, insider trading, stock sale, Rule 10b5-1, RMD, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.